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Background: Peptide receptor radionuclide therapy (PRRT) is routinely used for advanced or metastasized
neuroendocrine tumours (NET). To prevent nephrotoxicity, positively charged amino acids (AA) are co-infused.
The aim of this study was to correlate the risk for therapy-related hyperkalaemia with the total amount of AA
infused.
Methods: Twenty-two patients undergoing PRRT with standard activities of 177Lu-DOTATATE/-TOC were monitored
during two following treatment cycles with co-infusion of 75 and 50 g of AA (L-arginine and L-lysine), respectively.
Mean serum levels of potassium and other parameters (glomerular filtration rate [GFR], creatinine, blood urea nitrogen
[BUN], phosphate, chloride, lactate dehydrogenase) prior to, 4 h and 24 h after AA infusion were compared.
Results: Self-limiting hyperkalaemia (>5.0 mmol/l) resolving after 24 h occurred in 91% (20/22) of patients in both
protocols. Potassium levels, BUN, creatinine, GFR, phosphate, chloride and LDH showed a similar range at 4 h after
co-infusion of 75 or 50 g of AA, respectively (p > 0.05). Only GFR and creatinine levels at 24 h varied significantly
between the two co-infusion protocols (p < 0.05).
Conclusions: Hyperkalaemia is a frequent side effect of AA infusion in PRRT. Varying the dose of co-infused amino
acids did not impact on the incidence and severity of hyperkalaemia.
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Peptide receptor radionuclide therapy (PRRT) with radiola-
belled somatostatin agonists (90Y- or 177Lu-DOTATOC/-
TATE) is routinely used for advanced neuroendocrine
tumours (NET) or other entities such as meningioma
that overexpress somatostatin receptor subtype II (SSTR
II) [1-6]. Whereas the high-energy emitter 90Y was first
considered more effective, especially in bulky disease
[7], some studies reported on higher incidence and sever-
ity of side effects like myelosuppression and especially
renal toxicity [4,8]. Since the radiopeptide is reabsorbed
at the proximal tubule, subsequent retention may lead* Correspondence: werner_r1@ukw.de
†Equal contributors
1Department of Nuclear Medicine, University Hospital Würzburg,
Oberdürrbacher Str. 6, Würzburg 97080, Germany
Full list of author information is available at the end of the article
© 2014 Lapa et al.; licensee Springer. This is an
Attribution License (http://creativecommons.or
in any medium, provided the original work is pto excessive radiation doses and renal failure. In order
to prevent significant renal radiopeptide retention, posi-
tively charged amino acids (AA) such as L-arginine and
L-lysine have been introduced and are used in different
protocols for 1 or 2 days [9].
The AA bind to the tubular megalin/cubulin system
(which serves as a scavenger system for the reabsorption
of AA) and compete with the radiopeptide for reabsorp-
tion [10,11]. The co-administration leads to a significant
reduction in the renal absorbed dose [6,12]. However,
side effects like nausea, vomiting and hyperkalaemia have
been described [13,14]. Several authors have reported
on the influence of the composition and amount of AA
administered on serum potassium levels [11,13].
The aim of this study was to compare incidence and
severity of post-therapeutic hyperkalaemia (>5.0 mmol/l) in
patients undergoing PRRT with two different AA infusionOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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L-lysine.
Methods
Study design and characterization of the patient cohort
Twenty-two consecutive patients (13 males, 9 females)
referred for PRRT received 75 g of L-arginine and L-lysine
for the first cycle and 50 g of AA for the second cycle,
respectively. Mean age was 58 ± 14 years (range, 24 to
82 years). The general inclusion and exclusion criteria as
defined by The joint IAEA, EANM and SNMMI practical
guidance were applied [9]. Table 1 gives an overview on
patients' characteristics.
All patients gave written informed consent to the im-
plementation of standard-of-care PRRT. As this study
comprised exclusively retrospective analysis of routinely
acquired data, our institutional review board (ethics
committee of the Medical Faculty of the University of
Würzburg) waived the requirement for additional ap-
proval. In October 2013, the amount of AA routinely
administered was reduced from 75 to 50 g to comply
with the latest joint IAEA, EANM and SNMMI practical
guidance [9].Table 1 Main baseline features of the patients enrolled in the
Patient Age Sex Primary tumour
1 76 M Ileum NET
2 62 M Meningioma
3 61 M Pancreatic NET
4 82 F Pancreatic NET
5 50 M Rectal NET
6 67 F Liver NET
7 69 M Small bowel NET
8 50 F Pancreatic NET
9 49 M Small cell lung cancer
10 73 F Pancreatic NET
11 58 F Ileum NET
12 57 F Carcinoid
13 31 F Medullary thyroid cancer
14 24 M Ileum NET
15 66 M Thymus NET
16 60 F Meningioma
17 34 M Paraganglioma
18 61 M Small bowel NET
19 55 M Pancreatic NET
20 63 M Pancreatic NET
21 68 F Small bowel NET
22 54 M Cerebral NET
M male, F female, NET neuroendocrine tumour, LN lymph nodes, CTx chemotherapy
RTx radiotherapy.All patients were observed for two consecutive treat-
ment cycles. Admission occurred one day prior to PRRT
itself to allow for adequate hydration. During the first
treatment cycle, 1,500 ml of standard solution contain-
ing 37.5 g of arginine hydrochloride and 37.5 g of lysine
hydrochloride (pH, 7.0) was administered within 4 h (0.5
to 1 h prior to PRRT and for a total of 3 to 3.5 h after
therapy; infusion rate, 375 ml/h). For the second cycle,
25 g of each AA in a total of 2,000 ml saline was infused
within the same time period (0.5 to 1 h prior to PRRT
and for a total of 3 to 3.5 h after therapy; infusion rate,
500 ml/h) according to the most recent practical guidance
[9]. The AA solutions were produced in-house according
to GMP criteria.
For the first treatment cycle, a mean of 7.5 ± 0.7 GBq
of 177Lu-DOTATATE in 12 ml of normal saline was
intravenously infused over 30 min; for the second cycle,
7.6 ± 0.3 GBq of 177Lu-DOTATOC was administered.
Preparation of 177Lu-DOTATATE/-TOC
177Lu-DOTATATE/-TOC was prepared using a radiotracer
synthesis module (Scintomics, Fürstenfeldbruck, Germany)
with minor modifications as described before [15]. Briefly,study
Metastases Previous therapy
Liver Octreotide, interferon alfa
None None
Local vessel infiltration Stenting
Liver, bone Surgery
Bone Surgery
LN, muscle, brain Surgery
Liver, lung, LN None
Liver, LN Octreotide, everolimus, lanreotide
LN CTx
Bone, liver Surgery
Liver, LN Surgery, octreotide, thermoablation
Lung, bone Surgery, RCTx
Lung, LN, bone Surgery, CTx
Liver Surgery, TACE, octreotide
Bone, lung, LN None
None Surgery
Bone Surgery, RTx
Liver, LN Surgery, octreotide
Liver, LN CTx
LN, liver, bone Surgery
Liver, LN Surgery
Bone CTx
, RCTx radiochemotherapy, TACE transcatheter arterial chemoembolization,
Figure 1 Serum K+ levels. Serum K+ levels at baseline, 4 h
post-infusion and 24 h post-infusion (mmol/l; 50 g amino acid vs. 75 g
amino acid). **4 h in comparison to baseline (50 g/75 g): p < 0.001;
#4 h in comparison to 24 h (50 g/75 g): p < 0.001; *24 h in comparison
to baseline (50 g): p < 0.05. Empty bars show serum K+ concentrations
after administration of 50 g AA, and full bars show serum K+
concentrations after administration of 75 g AA.
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Radeberg, Germany) and 7 mg gentisic acid in 600 μl
sodium acetate buffer (pH = 4 to 5) was added to a so-
lution of 8 GBq 177LuCl3 in 0.04 M hydrochloric acid
(Isotope Technologies Garching, Garching, Germany)
and heated for 30 min at 95°C. The product was diluted
with saline and passed through a sterile filter (0.22 μm)
into a sterile vial. Radiochemical purity was determined
by gradient high-performance liquid chromatography
and thin layer chromatography. Additionally, the product
was also tested for pH, sterility and endotoxins.
Pre- and post-therapeutic blood samples
Blood samples of each patient were drawn to assess
standard blood values one day before PRRT and 4 and
24 h after AA infusion. Serum levels of potassium and
other parameters (glomerular filtration rate [GFR], cre-
atinine, blood urea nitrogen [BUN], phosphate, chlor-
ide, lactate dehydrogenase [LDH]) were compared. Whereas
hyperkalaemia is routinely defined by our laboratories as
serum K+ levels >5.0 mmol/l, severe hyperkalaemia was
arbitrarily defined as serum values ≥6.0 mmol. Serum po-
tassium levels were measured by indirect ion-sensitive
electrode (ISE) (Cobas 8000 system, Roche Diagnostics,
Mannheim, Germany). All samples were screened for
haemolysis. Absorbances of the diluted serum samples
(dilution 1:26) were measured at 570 nm (primary wave-
length) and at 600 nm (secondary wavelength), and the
haemolysis indices were calculated according to the
manufacturer's instruction. Serum samples with haemoly-
sis indices above 90 (equaling 90 mg/dl of free haemoglo-
bin) were considered to be haemolytic and excluded from
further evaluation (<5%).
Analysis and statistics
Statistical analyses were performed using PASW Statis-
tics software (version 22.0; SPSS, Inc. Chicago, IL,
USA). Quantitative values were expressed as mean ±
standard deviation and range as appropriate. Comparisons
of related metric measurements were performed using
Wilcoxon signed rank test.
Results
Post-PRRT clinical symptoms
After completion of PRRT, three patients of the 75 g group
presented with palpitations, chest pain and/or general
discomfort. Evaluation of ECG revealed flattened P waves
and high peaked T waves. Two of those three patients also
became symptomatic after administration of 50 g AA,
whereas the remaining tolerated this regimen without dis-
comfort. In all symptomatic cases, serum potassium levels
were ≥6.1 mmol/l with peak values of 7.9 mmol/l and re-
quired prompt intervention by infusion of 20 IU insulin
with 20% glucose in 500 ml saline.Besides, other side effects being not related to hyperka-
laemia were observed in both patient cohorts (e.g. nausea,
vomiting and decrease of kidney function).
At baseline, mean K+ levels were 4.4 ± 0.4 mmol/l
(75 g) and 4.3 ± 0.4 mmol/l (50 g), respectively. At 4 h,
20/22 subjects (91%) in both groups had serum potas-
sium levels ≥5.0 mmol/l with a mean of 5.8 ± 0.7 mmol/l
(75 g) and 5.7 ± 0.8 mmol/l (50 g), respectively. Increases
in K+ levels were comparable (25% for 75 g, p < 0.001
and 24% for 50 g AA, p < 0.001).
In both groups, severe hyperkalaemia defined as
K+ >6.0 mmol/l was observed in 8/22 (36%) patients.
After 24 h, K+ levels almost returned to baseline (mean,
4.5 ± 0.4 mmol/l (75 g AA) vs. mean, 4.6 ± 0.4 (50 g AA))
(Figure 1). No significant differences between both AA
protocols were found at any time point.
At 4 h post-infusion, all other parameters investigated
showed only minor differences. Only glomerular filtration
rates (p = 0.011) and creatinine levels at 24 h (p = 0.016)
varied significantly between 50 g of AA and 75 g of AA
(24 h post-infusion, 75 g vs. 50 g). Table 2 gives an over-
view of all biochemical parameters.
Discussion
This is the first intra-individual comparison of hyperka-
laemia induced by 50 or 75 g of nephroprotective amino
acids (Arg-Lys) in patients with neuroendocrine tumours
undergoing PRRT. Incidence and severity of hyperkalae-
mia (>5.0 mmol/l) were comparable for both protocols.
In PRRT, AA-induced hyperkalaemia is believed to re-
sult from the ketogenic characteristics of lysine, lowering
Table 2 Biochemical parameters at baseline, 4 h and 24 h after the beginning of amino acid (AA) infusion
Normal range Baseline
(75 g AA)
Baseline
(50 g AA)
p value
(baseline 75 g
vs. 50 g AA)
4 h
post-infusion
(75 g AA)
4 h
post-infusion
(50 g AA)
p value (4 h
post-infusion 75 g
vs. 50 g AA)
24 h
post-infusion
(75 g AA)
24 h
post-infusion
(50 g AA)
p value (24 h
post-infusion 75 g
vs. 50 g AA)
Potassium (mmol/l) 3.5-5 4.4 ± 0.4 4.3 ± 0.42 0.491 5.8 ± 0.7 5.7 ± 0.8 0.338 4.5 ± 0.4 4.6 ± 0.4 0.243
GFR (ml/min) >60 89.5 ± 27.1 89.4 ± 24.6 0.862 85.3 ± 24.8 84.0 ± 26.2 0.324 84.6 ± 26.2 93.2 ± 26.9 0.011
Creatinine (mg/dl) <0.95 0.89 ± 0.27 0.85 ± 0.28 0.444 0.92 ± 0.24 0.91 ± 0.26 0.952 0.93 ± 0.25 0.83 ± 0.19 0.016
BUN (mg/dl) 10-50 33.28 ± 12.86 30.91 ± 14.16 0.808 41.88 ± 12.23 40.2 ± 14.06 0.872 35.62 ± 13.81 34.7 ± 22.16 0.099
Phosphate (mmol/l) 0.87-1.45 1.08 ± 0.19 1.06 ± 0.17 0.601 0.85 ± 0.16 0.96 ± 0.16 0.167 1.16 ± 0.25 1.15 ± 0.24 0.074
Chloride (mmol/l) 94-110 99.00 ± 2.00 109.44 ± 27.95 0.180 106.00 ± 4.59 109.13 ± 2.29 0.102 103.55 ± 5.24 107.15 ± 2.67 0.157
LDH (U/l) <250 216.65 ± 66.11 205.04 ± 57.65 0.811 223.41 ± 55.08 257.18 ± 128.22 0.953 217.2 ± 52.58 247.69 ± 82.70 0.674
Values are means ± SD. GFR glomerular filtration rate, BUN blood urea nitrogen, LDH lactate dehydrogenase, mmol/l millimoles per litre, ml/min millilitres per minute, mg/dl milligrams per decilitre, U/l units per litre.
Values in italics denote significant difference.
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K+ flux [14]. Various publications have previously reported
on AA-induced increase of serum potassium levels. For ex-
ample, Barone and colleagues found just marginal increase
in K+ levels in patients treated with a mixture of arginine
and lysine totaling 50 g [11]. However, only six patients
were included in this study and blood samples were drawn
at an early time point (2.5 h after the start of infusion).
Recently, a group from Switzerland reported on hyperka-
laemia after administration of 25 g lysine and 25 g argin-
ine. In their cohort, serum potassium levels increased
significantly 4 h after the beginning of AA infusion [16].
Last, Rolleman et al. reported on even more pronounced
K+ increases induced by 75 g of lysine, warning of AA-
induced hyperkalaemia. In our cohort, we observed higher
values of potassium than previously reported [13]. The
reason for this observation is not fully understood. In
order to rule out spurious hyperkalaemia, blood haemoly-
sis indices were calculated. One possible explanation
might be the pH value of the amino acid solution adminis-
tered, which in our department is 7.0. Serum acidosis is
known to be associated with potassium movement from
the cellular space into the extracellular fluid in order to
buffer excess hydrogen ions. The rather high volume in-
fusion of 1,500 ml of AA might affect serum pH and
thereby subsequently influence serum potassium. The
total amount of AA solution administered did not influ-
ence incidence or severity of hyperkalaemia. Therefore,
our data hint at a major contribution of the pH of the
AA solution which was the same in all cycles.
Both infusion protocols were equally well tolerated.
Most of the patients experienced asymptomatic rises in
K+, and symptoms resolved quickly within 24 h without
any further intervention. Three patients became symp-
tomatic including palpitations, chest pain and general
discomfort. Two of those three patients suffered from
hyperkalaemia-related side effects regardless of the amount
of AA infused, whereas the remaining subject only ex-
perienced discomfort with 75 g of AA. Interestingly, this
subject had lower K+ values after administration of 50 g
AA (6.1 mmol/l) as compared to 75 g AA (7.0 mmol/l). In
all, treatment with insulin and glucose was highly effective
and symptoms were relieved quickly.
Changes in other serum parameters included a non-
significant decrease in phosphate, increase in BUN or
changes in chloride which were also not significant,
consistent with studies published before [16]. Also, no
significant changes in kidney function were observed.
According to our study, only a transient increase of
serum creatinine after start of the AA infusion has
been reported [11] and might be associated with higher
doses of AA due to non-specific tubular cell blockade.
Resolution was observed after 24 h. In short, hyperkalae-
mia as an adverse event to a potentially life-threateningdegree has to be kept in mind regardless of the AA proto-
col used for PRRT.
The following limitations have to be considered: firstly,
the retrospective study design and the low patient number
may be associated with a significant sample bias. Secondly,
this study does not allow any conclusions regarding the
nephroprotective effect of the different AA amounts.
Therefore, future prospective studies with larger patient
numbers need to be performed, potentially also inves-
tigating the long-term effectiveness and safety of AA
co-infusion protocols with even lower AA amounts.
However, to the best of our knowledge, this is the first
report on an intra-individual comparison of two different
AA protocols.
Conclusions
Transient hyperkalaemia is a frequent side effect of AA
co-infusion during PRRT. In contrast to previous reports,
incidence and severity of hyperkalaemia do not significantly
vary between different amounts of AA administered.
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